查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000848

單光子發射電腦斷層掃描（SPECT）市場：按產品、檢測器、應用和最終用戶分類－2026-2032年全球市場預測

Single Photon Emission Computed Tomography Market by Product, Detector, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

單光子發射電腦斷層掃描 (SPECT) 市場預計到 2025 年將達到 22.8 億美元，到 2026 年將成長到 23.7 億美元，到 2032 年將達到 30.2 億美元，複合年成長率為 4.09%。

主要市場統計數據
基準年 2025 22.8億美元
預計年份：2026年 23.7億美元
預測年份 2032 30.2億美元
複合年成長率 (%) 4.09%

為診斷領域的領導者提供當前 SPECT 趨勢的簡要概述，重點關注臨床相關性、技術變革和採購考慮因素。

單光子發射電腦斷層掃描（SPECT）仍然是核子醫學的基石技術，它將功能性影像與循環系統、神經病學和腫瘤學等領域的廣泛臨床效用相結合。過去十年來的技術進步已使該技術從類比檢測器範式轉變為數位和固態架構，從而提高了計數靈敏度、空間解析度和工作流程整合度。這些進步，加上放射性藥物物流、影像通訊協定和臨床路徑的變化，正在影響診斷中心和醫院系統的應用和升級週期。

檢測器、人工智慧重建和不斷發展的臨床工作流程方面的突破如何重新定義 SPECT 成像在診斷中的期望和籌資策略。

SPECT領域正經歷一場變革，這主要得益於檢測器創新、智慧軟體和不斷發展的臨床工作流程的整合。新型檢測器技術正推動系統從大型碘化鈉晶體轉向緊湊型碲化鋅鎘（CZT）和先進的固體感測器，從而提供獨特的能量解析度並縮短死時間。同時，影像重建演算法和人工智慧驅動的後處理正在提升病灶的檢出和定量能力，並改變人們對診斷準確性和報告時間的預期。

我們將評估累積關稅措施對 SPECT 系統製造商和醫療保健提供者的供應鏈、採購計劃和籌資策略的影響。

美國近期採取的關稅措施引發了全球醫療設備供應鏈的高度敏感性，對SPECT系統的製造商、經銷商和最終用戶都產生了累積影響。半導體檢測器、精密機械零件和專用電子元件等組件極易受到關稅帶來的成本壓力，這可能導致最終成本上升，並使醫院和診斷中心的設備採購流程更加複雜。為此，製造商正在重新評估採購地點和供應契約，以降低風險並確保產品供應。

檢測器技術、最終用戶優先事項、產品架構和臨床應用與採購和臨床策略聯繫起來的基於詳細細分的見解。

檢測器技術的細分揭示了臨床應用優先事項的明顯差異。先進的固體檢測器，包括碲化鎘鋅檢測器、鍺半導體和矽光電倍增器，因其卓越的能量解析度和計數靈敏度而備受青睞，尤其是在需要檢測微小病灶的應用中。相較之下，碘化鈉閃爍偵測器在成本效益和成熟工作流程至關重要的領域仍然佔據主導地位，並在許多高通量診斷中心保持領先地位。檢測器的這些差異不僅影響影像質量，還會影響維護需求、培訓需求，甚至資本投資決策。

影響 SPECT 系統採購、部署和維護的美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和部署模式。

區域趨勢顯著影響SPECT系統的部署模式和策略重點，尤其是在美洲地區。該地區對先進心臟影像的需求集中，並已形成強大的供應商生態系統，能夠迅速將創新的檢測器技術轉化為臨床應用。在美洲地區，私人影像中心和醫院網路通常優先考慮處理能力和綜合服務契約，這為模組化系統升級和高性能檢測器的應用創造了有利環境。法規環境和報銷機制也進一步影響新技術在臨床環境中的評估和應用方式。

競爭定位、卓越服務以及硬體創新者和軟體開發商之間的夥伴關係如何影響 SPECT 供應商格局？

SPECT生態系統內的競爭動態主要由跨國影像設備製造商及專注於檢測器創新及特定臨床解決方案的專業公司所主導。大型成熟的醫療影像公司利用其全球服務網路和整合的產品系列，與醫療機構簽訂契約，並提供可預測的全生命週期支援。同時，小規模的專業公司則透過尖端的檢測器技術、緊湊的機殼或軟體主導的影像校正功能來脫穎而出。設備製造商和軟體開發商之間的夥伴關係日益重要，這使得重建演算法和人工智慧輔助診斷工具能夠不斷迭代更新。

在實施 SPECT 技術時，醫療保健主管和供應商在協調採購、臨床效用和供應鏈彈性方面面臨的實際策略挑戰。

計劃投資SPECT技術的產業領導者應優先考慮模組化、供應鏈韌性和與臨床需求的契合度，以做出面向未來的資本決策。在選擇新系統時，決策者應要求具備靈活的升級路徑，以便在不更換整個系統的情況下改進檢測器和軟體。這既能保護資本，又能根據不斷變化的臨床需求提升效能。籌資策略還應包含供應商多元化和合約保障措施，以降低關稅和地緣政治因素造成的供應中斷風險。

為了確保對 SPECT 技術有可靠和透明的了解，我們採用了嚴謹的多方面研究途徑，結合了對臨床醫生的訪談、技術檢驗和二手文獻的整合。

本研究採用多方面方法，交叉檢驗了關鍵相關人員的意見、精心挑選的二手資料以及技術檢驗。主要研究包括對臨床終端使用者、影像物理學家、採購負責人和設備工程師進行結構化訪談，以了解他們對效能要求、操作挑戰和服務期望的實際觀點。此外，還諮詢了監管專家，以解讀核准流程和合規性對設備部署計畫的影響，從而補充了這些定性見解。

對決定 SPECT 成功實施和長期臨床價值的技術、操作和策略因素進行全面分析。

總而言之，SPECT 仍然是一種至關重要且適應性極強的成像技術，其短期前景將取決於檢測器創新、軟體帶來的影像品質提升以及由營運重點和供應鏈趨勢驅動的採購模式轉變。積極將技術選擇與臨床應用案例結合、優先考慮模組化升級、完善的服務合約和實證實踐的相關人員，將更有利於把技術進步轉化為診斷信心和患者管理能力的顯著提升。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 單光子發射電腦斷層掃描（SPECT）市場：依產品分類

  • 雙頭
  • 單頭
  • 三頭

第9章：單光子發射電腦斷層掃描（SPECT）市場（檢測器類型分類）

  • Czt
  • 碘化鈉閃爍
  • 固體的
    • 鍺半導體
    • 矽光電倍增器

第10章 單光子發射電腦斷層掃描（SPECT）市場：依應用領域分類

  • 循環系統
  • 神經病學
  • 腫瘤學

第11章 單光子發射電腦斷層掃描（SPECT）市場：依最終使用者分類

  • 診斷中心
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究機構

第12章 單光子發射電腦斷層掃描（SPECT）市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 單光子發射電腦斷層掃描（SPECT）市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 單光子發射電腦斷層掃描（SPECT）市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國單光子發射電腦斷層掃描（SPECT）市場

第16章：中國的單光子發射電腦斷層掃描（SPECT）市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Cyclotron Systems, Inc.
  • Agfa-Gevaert NV
  • Beijing Hamamatsu Photon Techniques Inc.
  • Bracco Imaging SpA
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • CardiArc, Ltd.
  • Cardinal Health, Inc.
  • Curium
  • DDD-Diagnostic A/S
  • Digirad Corporation
  • Gamma Medica, Inc.
  • GE HealthCare Technologies Inc.
  • Global Medical Solutions, Ltd.
  • Hitachi, Ltd.
  • Hologic, Inc.
  • Koninklijke Philips NV
  • Lantheus Holdings, Inc.
  • Mediso Medical Imaging Systems Ltd.
  • MiE GmbH Medical Imaging Electronics
  • MILabs BV
  • Neusoft Medical Systems Co., Ltd.
  • Novartis AG
  • NTP Radioisotopes SOC Ltd
  • Nucare, Inc.
  • Parto Negar Persia Co.
  • Positron Corporation
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Spectrum Dynamics Medical Ltd.
Product Code: MRR-02026C4CB810

The Single Photon Emission Computed Tomography Market was valued at USD 2.28 billion in 2025 and is projected to grow to USD 2.37 billion in 2026, with a CAGR of 4.09%, reaching USD 3.02 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.28 billion
Estimated Year [2026] USD 2.37 billion
Forecast Year [2032] USD 3.02 billion
CAGR (%) 4.09%

A concise introduction to the current SPECT landscape highlighting clinical reliance, technological shifts, and procurement considerations for diagnostic leaders

Single Photon Emission Computed Tomography (SPECT) remains a cornerstone modality in nuclear medicine, combining functional imaging with widespread clinical utility across cardiology, neurology, and oncology. Technological evolution over the last decade has shifted the modality from analog detector paradigms toward digital and solid-state architectures, enabling improved count sensitivity, spatial resolution, and workflow integration. These advances are occurring in parallel with changes in radiopharmaceutical logistics, imaging protocols, and clinical pathways that collectively influence adoption and upgrade cycles in diagnostic centers and hospital systems.

Clinicians continue to rely on SPECT for myocardial perfusion imaging, brain perfusion assessments, and targeted oncologic studies where metabolic and receptor-based imaging complements anatomical techniques. As healthcare systems emphasize value-based outcomes and diagnostic efficiency, SPECT's adaptability-through diverse detector technologies and modular product configurations-supports a range of clinical use cases from high-volume cardiology labs to specialized research institutes. Consequently, procurement leaders and imaging directors must weigh clinical requirements, facility throughput, and lifecycle costs when planning equipment refreshes or new deployments.

Transitioning from established practice to innovation-led deployment requires careful alignment of technical performance with clinical protocols. Therefore, stakeholders should appraise detector options, head configurations, and service models in light of evolving clinical guidelines and operational priorities to ensure systems deliver measurable improvements in diagnostic confidence and patient throughput.

How detector breakthroughs, AI-driven reconstruction, and evolving clinical workflows are redefining diagnostic expectations and procurement strategies in SPECT imaging

The SPECT landscape is undergoing transformative shifts driven by convergence of detector innovation, software intelligence, and altered clinical workflows. New detector technologies are moving systems away from large-volume sodium iodide crystals toward compact cadmium zinc telluride and advanced solid-state sensors that offer intrinsic energy resolution and reduced dead time. Concurrently, image reconstruction algorithms and AI-enabled post-processing are enhancing lesion detectability and quantification, which is changing expectations for diagnostic accuracy and reporting timelines.

Operationally, hybrid imaging strategies and multimodality integration are reshaping how SPECT is positioned within diagnostic pathways; clinicians increasingly combine functional SPECT data with CT-derived attenuation correction and anatomical correlation, improving diagnostic confidence. At the same time, shifts in healthcare delivery-such as outpatient imaging consolidation and the proliferation of dedicated cardiac imaging centers-are altering procurement priorities toward systems that balance throughput with cost-efficiency. Supply chain dynamics and regulatory evolution are also prompting manufacturers and adopters to pursue diversified sourcing strategies and modular upgrade paths.

Taken together, these shifts create both opportunity and complexity: opportunities to enhance clinical utility and patient-centric workflows, and complexity in aligning technology selection with long-term serviceability, radiopharmaceutical availability, and evolving reimbursement models. Strategic planning must therefore reconcile rapid technological progress with sustainable operational models.

Assessing how cumulative tariff actions are reshaping supply chains, procurement timelines, and sourcing strategies for SPECT system manufacturers and healthcare providers

Recent tariff measures in the United States have introduced heightened sensitivity across global medical device supply chains, with cumulative implications for manufacturers, distributors, and end users of SPECT systems. Components such as semiconductor detectors, precision mechanical parts, and specialized electronics are vulnerable to tariff-induced cost pressures, which can increase landed costs and complicate capital procurement cycles for hospitals and diagnostic centers. In response, manufacturers are reassessing sourcing footprints and supply contracts to mitigate exposure while preserving product availability.

Consequently, many suppliers have accelerated localization of key components, established alternate supplier relationships, and adjusted logistics strategies to reduce tariff risk. These adaptations often entail nearshoring assembly operations, renegotiating supplier terms, and redesigning product architectures to use more readily sourced subsystems. Procurement teams are reacting by extending lead times in capital planning and prioritizing supplier stability and long-term service agreements over short-term price advantages.

From an operational standpoint, imaging centers may encounter longer procurement timelines and elevated acquisition costs that influence upgrade pacing and prioritization of high-throughput installations. Clinicians and administrators should therefore factor tariff-related supply chain uncertainty into capital planning, replacing assumptions of stable component availability with scenario-based procurement roadmaps that emphasize flexibility, lifecycle service support, and contractual protections against volatile input costs.

Deep segmentation-driven insights linking detector technologies, end-user priorities, product architectures, and clinical applications to procurement and clinical strategy

Detector technology segmentation reveals a clear divergence in clinical priorities: cadmium zinc telluride detectors and advanced solid-state options, including germanium semiconductors and silicon photomultipliers, are valued for superior energy resolution and count sensitivity, particularly in applications requiring small-lesion detection. By contrast, sodium iodide scintillation remains prevalent where cost efficiency and established workflows dominate, sustaining its presence in many diagnostic centers with large imaging volumes. These detector distinctions influence not only image quality but also service requirements, training needs, and capital allocation decisions.

End-user segmentation highlights differentiated procurement drivers across diagnostic centers, hospitals, and research institutes. Diagnostic centers prioritize throughput and cost-per-scan efficiency and therefore often favor systems with simplified workflows and rapid reconstruction. Hospitals, both private and public, balance clinical versatility with budgetary constraints; private hospitals may prioritize premium detectors and integrated service packages to support competitive positioning, whereas public hospitals frequently emphasize robust uptime, standardized protocols, and long-term maintenance contracts. Research institutes favor configurability and advanced detection technologies that enable protocol development and exploratory applications.

Product configuration also informs purchasing decisions: single-head systems appeal in space-constrained or low-volume settings, dual-head instruments offer balanced throughput and flexibility for general cardiology and oncology applications, and triple-head systems are selected where high sensitivity and faster acquisition are essential. Application segmentation into cardiology, neurology, and oncology continues to shape system requirements, with cardiology driving demand for rapid gated protocols, neurology emphasizing perfusion quantification, and oncology requiring compatibility with targeted tracers and quantitative workflows. Collectively, these segmentation layers determine the technical specifications, service models, and acquisition priorities that stakeholders must reconcile when selecting SPECT solutions.

Regional dynamics and adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence procurement, deployment, and serviceability of SPECT systems

Regional dynamics exert strong influence over adoption patterns and strategic priorities for SPECT systems, with the Americas exhibiting concentrated demand in advanced cardiac imaging and a robust vendor ecosystem that supports rapid clinical translation of detector innovations. In this region, private imaging centers and hospital networks often prioritize throughput and integrated service agreements, creating fertile ground for modular system upgrades and premium detector deployments. Regulatory environments and reimbursement frameworks further shape how new technologies are evaluated and adopted in clinical practice.

In Europe, the Middle East and Africa, the landscape is more heterogeneous; high-income European markets show steady uptake of advanced digital detectors and hybrid workflows, while markets across the Middle East and Africa are characterized by selective investments concentrated in tertiary hospitals and specialty centers. These geographies often emphasize reliability and long-term serviceability, given the logistical complexities of cross-border parts supply. Meanwhile, Asia-Pacific demonstrates rapid modernization in imaging infrastructure, driven by expanding middle-class healthcare demand, investment in specialized cardiac and oncologic centers, and local manufacturing initiatives that can lower acquisition barriers for advanced detector systems.

Across all regions, localized factors such as radiopharmaceutical availability, training ecosystems, and healthcare policy priorities shape how facilities prioritize upgrades and deploy SPECT systems. As a result, regional strategy must integrate clinical needs, supply chain resilience, and regulatory compliance to optimize deployment and ensure sustainable operations.

How competitive positioning, service excellence, and partnerships between hardware innovators and software developers are shaping the SPECT vendor landscape

Competitive dynamics in the SPECT ecosystem are governed by a mix of multinational imaging manufacturers and specialized firms that emphasize detector innovation or niche clinical solutions. Large, established medical imaging companies continue to leverage global service networks and integrated product portfolios to secure institutional contracts and deliver predictable lifecycle support, while smaller specialists differentiate through cutting-edge detector technologies, compact form factors, or software-driven image enhancement. Partnerships between device manufacturers and software developers are increasingly important, enabling iterative updates to reconstruction algorithms and AI-supported diagnostic aids.

Service and aftermarket support represent a decisive competitive axis: vendors that offer comprehensive training programs, predictive maintenance, and rapid parts availability tend to secure longer-term contracts with hospitals and diagnostic chains. Additionally, collaborative initiatives with radiopharmaceutical suppliers and clinical research organizations strengthen a supplier's value proposition by facilitating multi-center studies and protocol standardization. Capital equipment procurement committees and imaging directors therefore evaluate vendors not only on device performance but on the total cost of ownership, upgrade pathways, and demonstrated clinical outcomes.

Innovation pipelines focus on detector miniaturization, enhanced energy discrimination, and software platforms that improve quantitative reporting. This combination of hardware and software advancement provides new entrants with avenues to challenge incumbent offerings, while incumbents invest in acquisition, partnership, and internal R&D programs to maintain relevance. Ultimately, competitive success depends on aligning technical differentiation with dependable service models and evidence of clinical impact.

Actionable strategic imperatives for healthcare executives and vendors to align procurement, clinical utility, and supply chain resilience when adopting SPECT technologies

Industry leaders planning investments in SPECT technology should prioritize modularity, supply chain resilience, and clinical alignment to future-proof capital decisions. When specifying new systems, decision-makers should require flexible upgrade paths that allow detector or software improvements without full system replacement, thereby protecting capital while enabling performance enhancements as clinical needs evolve. Procurement strategies must also incorporate supplier diversification and contractual protections to mitigate tariff-driven and geopolitical supply disruptions.

Clinically, organizations should align acquisition criteria with high-impact applications: prioritize systems that demonstrably improve diagnostic confidence in cardiology, neurology, or oncology workflows and that integrate seamlessly with PACS and reporting infrastructures. Investing in staff training and protocol harmonization enhances the clinical value of advanced detectors and reconstruction software, ensuring that improved imaging performance translates into better patient management. From an operational perspective, emphasize total lifecycle support agreements and spare-part logistics to maximize uptime and predictable operating costs.

Finally, collaboration with industry partners on pilot studies and phased rollouts can de-risk adoption while generating local evidence of clinical and operational benefits. By combining flexible technical specifications with robust service frameworks and evidence-generating partnerships, leaders can secure imaging assets that deliver sustained clinical value and operational resilience.

A rigorous multi-method research approach combining clinician interviews, technical validation, and secondary literature synthesis to ensure reliable and transparent insights into SPECT technologies

This research was developed using a multi-method approach that triangulates primary stakeholder inputs with curated secondary sources and technical validation. Primary research included structured interviews with clinical end users, imaging physicists, procurement officers, and device engineers to capture frontline perspectives on performance requirements, operational challenges, and service expectations. These qualitative insights were supplemented by consultations with regulatory specialists to interpret approval pathways and compliance implications that affect device deployment timelines.

Secondary research encompassed peer-reviewed literature, clinical guidelines, manufacturer technical specifications, and publicly available regulatory filings to establish a robust evidence base on detector performance characteristics, imaging protocols, and application-specific requirements. Quantitative cross-checks were performed where feasible through anonymized procurement case studies and device lifecycle records provided by participating institutions. Throughout the process, data validation techniques such as source triangulation, consistency checks, and expert panel review were applied to ensure analytic rigor and mitigate potential bias.

The methodology emphasizes transparency and reproducibility: assumptions are documented, interview instruments are archived, and the analytical framework is designed to accommodate updates as new clinical evidence and technological developments emerge. Stakeholders seeking methodological clarification or bespoke analysis were invited to engage directly with the research team for tailored validation exercises.

Concluding synthesis of technological, operational, and strategic factors that will determine successful SPECT adoption and long-term clinical value

In conclusion, SPECT remains a vital and adaptable imaging modality whose near-term trajectory is defined by detector innovation, software-enabled image quality gains, and shifting procurement paradigms driven by operational priorities and supply chain dynamics. Stakeholders that proactively align technical selections with clinical use cases-prioritizing modular upgrades, robust service agreements, and evidence generation-will be best positioned to translate technological advances into measurable improvements in diagnostic confidence and patient throughput.

Tariff-related supply chain disruptions and regional heterogeneity underscore the need for flexible sourcing strategies and scenario-based procurement planning. Meanwhile, the competitive landscape rewards vendors that couple hardware differentiation with dependable aftermarket support and collaborative evidence-generation efforts. As the clinical community continues to demand higher resolution, faster acquisitions, and quantitative outputs, the combination of advanced detectors and intelligent reconstruction will shape the next wave of SPECT deployments.

Moving forward, organizations should balance innovation adoption with operational resilience, ensuring that investments in SPECT technology are underpinned by training, standardized protocols, and supplier relationships that support long-term clinical and financial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Single Photon Emission Computed Tomography Market, by Product

  • 8.1. Dual Head
  • 8.2. Single Head
  • 8.3. Triple Head

9. Single Photon Emission Computed Tomography Market, by Detector

  • 9.1. Czt
  • 9.2. Nai Scintillation
  • 9.3. Solid State
    • 9.3.1. Germanium Semiconductor
    • 9.3.2. Silicon Photomultiplier

10. Single Photon Emission Computed Tomography Market, by Application

  • 10.1. Cardiology
  • 10.2. Neurology
  • 10.3. Oncology

11. Single Photon Emission Computed Tomography Market, by End User

  • 11.1. Diagnostic Centers
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Research Institutes

12. Single Photon Emission Computed Tomography Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Single Photon Emission Computed Tomography Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Single Photon Emission Computed Tomography Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Single Photon Emission Computed Tomography Market

16. China Single Photon Emission Computed Tomography Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Advanced Cyclotron Systems, Inc.
  • 17.6. Agfa-Gevaert N.V.
  • 17.7. Beijing Hamamatsu Photon Techniques Inc.
  • 17.8. Bracco Imaging S.p.A.
  • 17.9. Bruker Corporation
  • 17.10. Canon Medical Systems Corporation
  • 17.11. CardiArc, Ltd.
  • 17.12. Cardinal Health, Inc.
  • 17.13. Curium
  • 17.14. DDD-Diagnostic A/S
  • 17.15. Digirad Corporation
  • 17.16. Gamma Medica, Inc.
  • 17.17. GE HealthCare Technologies Inc.
  • 17.18. Global Medical Solutions, Ltd.
  • 17.19. Hitachi, Ltd.
  • 17.20. Hologic, Inc.
  • 17.21. Koninklijke Philips N.V.
  • 17.22. Lantheus Holdings, Inc.
  • 17.23. Mediso Medical Imaging Systems Ltd.
  • 17.24. MiE GmbH Medical Imaging Electronics
  • 17.25. MILabs B.V.
  • 17.26. Neusoft Medical Systems Co., Ltd.
  • 17.27. Novartis AG
  • 17.28. NTP Radioisotopes SOC Ltd
  • 17.29. Nucare, Inc.
  • 17.30. Parto Negar Persia Co.
  • 17.31. Positron Corporation
  • 17.32. Shimadzu Corporation
  • 17.33. Siemens Healthineers AG
  • 17.34. Spectrum Dynamics Medical Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DUAL HEAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DUAL HEAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DUAL HEAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SINGLE HEAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SINGLE HEAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SINGLE HEAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY TRIPLE HEAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY TRIPLE HEAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY TRIPLE HEAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CZT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CZT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CZT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NAI SCINTILLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NAI SCINTILLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NAI SCINTILLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY GERMANIUM SEMICONDUCTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY GERMANIUM SEMICONDUCTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY GERMANIUM SEMICONDUCTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SILICON PHOTOMULTIPLIER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SILICON PHOTOMULTIPLIER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SILICON PHOTOMULTIPLIER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 121. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 124. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 125. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 142. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 144. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 145. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 146. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 151. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 152. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 153. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)